Mario C Raviglione

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6860368/publications.pdf

Version: 2024-02-01

237 papers	29,306 citations	5268 83 h-index	5120 166 g-index
242 all docs	242 docs citations	242 times ranked	20423 citing authors

#	Article	IF	Citations
1	Global Burden of Tuberculosis. JAMA - Journal of the American Medical Association, 1999, 282, 677.	7.4	2,526
2	The Growing Burden of Tuberculosis. Archives of Internal Medicine, 2003, 163, 1009.	3.8	2,147
3	WHO's new End TB Strategy. Lancet, The, 2015, 385, 1799-1801.	13.7	834
4	Tuberculosis. Nature Reviews Disease Primers, 2016, 2, 16076.	30.5	830
5	Drivers of tuberculosis epidemics: The role of risk factors and social determinants. Social Science and Medicine, 2009, 68, 2240-2246.	3.8	775
6	Global Epidemiology of Tuberculosis. JAMA - Journal of the American Medical Association, 1995, 273, 220.	7.4	750
7	WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. European Respiratory Journal, 2011, 38, 516-528.	6.7	718
8	Global Surveillance for Antituberculosis-Drug Resistance, 1994â€“1997. New England Journal of Medicine, 1998, 338, 1641-1649.	27.0	713
9	Tuberculosis control and elimination 2010â€“50: cure, care, and social development. Lancet, The, 2010, 375, 1814-1829.	13.7	697
10	Tuberculosis. New England Journal of Medicine, 2013, 368, 745-755.	27.0	636
11	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	6.7	608
12	LatentMycobacterium tuberculosisInfection. New England Journal of Medicine, 2015, 372, 2127-2135.	27.0	578
13	Global Trends in Resistance to Antituberculosis Drugs. New England Journal of Medicine, 2001, 344, 1294-1303.	27.0	567
14	Management of latentMycobacterium tuberculosisinfection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, 2015, 46, 1563-1576.	6.7	475
15	Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. European Respiratory Journal, 2014, 43, 1763-1775.	6.7	423
16	Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis. JAMA - Journal of the American Medical Association, 2000, 283, 2537.	7.4	417
17	Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally. JAMA - Journal of the American Medical Association, 2005, 293, 2767.	7.4	398
18	Epidemiology of antituberculosis drug resistance 2002â€“07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet, The, 2009, 373, 1861-1873.	13.7	353

#	Article	IF	Citations
19	XDR Tuberculosis â€" Implications for Global Public Health. New England Journal of Medicine, 2007, 356, 656-659.	27.0	341
20	WHO's new Stop TB Strategy. Lancet, The, 2006, 367, 952-955.	13.7	340
21	Prospects for Tuberculosis Elimination. Annual Review of Public Health, 2013, 34, 271-286.	17.4	312
22	The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respiratory Medicine,the, 2018, 6, 299-314.	10.7	311
23	International Standards for Tuberculosis Care. Lancet Infectious Diseases, The, 2006, 6, 710-725.	9.1	308
24	Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet, The, 2012, 379, 1902-1913.	13.7	300
25	Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug) Tj ETQq1 1 0.784314 rgBT /Overlock 10	13.7	294
26	Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis. Science, 2002, 295, 2042-2046.	12.6	289
27	Trends in tuberculosis incidence and their determinants in 134 countries. Bulletin of the World Health Organization, 2009, 87, 683-691.	3.3	282
28	Drug-Resistant Tuberculosis: Review of the Worldwide Situation and the WHO/IUATLD Global Surveillance Project. Clinical Infectious Diseases, 1997, 24, S121-S130.	5.8	279
29	European framework for tuberculosis control and elimination in countries with a low incidence. European Respiratory Journal, 2002, 19, 765-775.	6.7	268
30	Zoonotic tuberculosis in human beings caused by Mycobacterium bovis â€"a call for action. Lancet Infectious Diseases, The, 2017, 17, e21-e25.	9.1	265
31	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	13.7	257
32	Global Epidemiology of Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 271-285.	2.1	250
33	Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infectious Diseases, The, 2013, 13, 529-539.	9.1	243
34	Global Epidemiology of Tuberculosis: Prospects for Control. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 481-491.	2.1	240
35	Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007â€"2010. Bulletin of the World Health Organization, 2012, 90, 111-119D.	3.3	230
36	The WHO policy package to combat antimicrobial resistance. Bulletin of the World Health Organization, 2011, 89, 390-392.	3.3	227

#	Article	IF	Citations
37	The TB epidemic from 1992 to 2002. Tuberculosis, 2003, 83, 4-14.	1.9	221
38	Tuberculosis control in the era of HIV. Nature Reviews Immunology, 2005, 5, 819-826.	22.7	216
39	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. European Respiratory Journal, 2013, 42, 252-271.	6.7	211
40	Private practitioners and public health: weak links in tuberculosis control. Lancet, The, 2001, 358, 912-916.	13.7	204
41	Global tuberculosis control: lessons learnt and future prospects. Nature Reviews Microbiology, 2012, 10, 407-416.	28.6	199
42	European Union Standards for Tuberculosis Care. European Respiratory Journal, 2012, 39, 807-819.	6.7	188
43	Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet, The, 2002, 359, 1980-1989.	13.7	185
44	Evolution of WHO policies for tuberculosis control, 1948â€“2001. Lancet, The, 2002, 359, 775-780.	13.7	181
45	Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal, 2007, 30, 623-626.	6.7	179
46	Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination. Gastroenterology Insights, 2016, 8, 6570.	1.2	175
47	Assessment of worldwide tuberculosis control. Lancet, The, 1997, 350, 624-629.	13.7	172
48	MDR Tuberculosis â€" Critical Steps for Prevention and Control. New England Journal of Medicine, 2010, 363, 1050-1058.	27.0	168
49	125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?. European Respiratory Journal, 2007, 29, 423-427.	6.7	166
50	Global Epidemiology of Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a017798-a017798.	6.2	163
51	New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future. Journal of Infectious Diseases, 2012, 205, S241-S249.	4.0	159
52	The Global Fight Against HIV/AIDS, Tuberculosis, and Malaria. American Journal of Clinical Pathology, 2009, 131, 844-848.	0.7	158
53	Multidrug-resistant Tuberculosis Management in Resource-limited Settings. Emerging Infectious Diseases, 2006, 12, 1389-1397.	4.3	152
54	Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infectious Diseases, The, 2016, 16, 1185-1192.	9.1	151

#	Article	IF	Citations
55	Tuberculosis elimination: theory and practice in Europe. European Respiratory Journal, 2014, 43, 1410-1420.	6.7	148
56	Extrapulmonary Pneumocystosis: The First 50 Cases. Clinical Infectious Diseases, 1990, 12, 1127-1138.	5.8	143
57	Drug-Resistant Tuberculosisâ€"Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs. Journal of Infectious Diseases, 2012, 205, S228-S240.	4.0	140
58	Systematic screening for active tuberculosis: rationale, definitions and key considerations [State of the art series. Active case finding/screening. Number 1 in the series]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 289-298.	1.2	138
59	Infections associated with hickman catheters in patients with acquired immunodeficiency syndrome. American Journal of Medicine, 1989, 86, 780-786.	1.5	132
60	Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infectious Diseases, The, 2006, 6, 483-495.	9.1	132
61	The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 148-150.	1.8	132
62	Global Epidemiology of Tuberculosis. Clinics in Chest Medicine, 2005, 26, 167-182.	2.1	127
63	Global Epidemiology of Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 003-016.	2.1	123
64	PUBLIC HEALTH: Responding to Market Failures in Tuberculosis Control. Science, 2001, 293, 1049-1051.	12.6	120
65	Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infectious Diseases, The, 2018, 18, 675-683.	9.1	119
66	Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. European Respiratory Journal, 2011, 37, 1269-1282.	6.7	116
67	TUBERCULOSIS: EPIDEMIOLOGY AND CONTROL. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014070.	1.3	116
68	Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet, The, 2010, 375, 2179-2191.	13.7	114
69	Surveillance of tuberculosis in Europe. European Respiratory Journal, 1996, 9, 1097-1104.	6.7	111
70	Beyond UHC: Monitoring Health and Social Protection Coverage in the Context of Tuberculosis Care and Prevention. PLoS Medicine, 2014, 11, e1001693.	8.4	110
71	The impact of social protection and poverty elimination on global tuberculosis incidence: a statistical modelling analysis of Sustainable Development Goal 1. The Lancet Global Health, 2018, 6, e514-e522.	6.3	110
72	Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance. New England Journal of Medicine, 2016, 375, 1081-1089.	27.0	109

#	Article	IF	Citations
73	Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. European Respiratory Review, 2019, 28, 190035.	7.1	107
74	New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine, 2010, 16, 1.	2.6	106
75	Multidrug-resistant tuberculosis around the world: what progress has been made?. European Respiratory Journal, 2015, 45, 150-160.	6.7	104
76	Multidrug-resistant and extensively drug-resistantMycobacterium tuberculosis: epidemiology and control. Expert Review of Anti-Infective Therapy, 2007, 5, 857-871.	4.4	101
77	Increasing transparency in partnerships for health - introducing the Green Light Committee. Tropical Medicine and International Health, 2002, 7, 970-976.	2.3	100
78	Prevention, Diagnosis, and Treatment of Tuberculosis in Children and Mothers: Evidence for Action for Maternal, Neonatal, and Child Health Services. Journal of Infectious Diseases, 2012, 205, S216-S227.	4.0	98
79	Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrobial Agents and Chemotherapy, 1990, 34, 2050-2054.	3.2	96
80	Extensively Drug-resistant Tuberculosis, Italy and Germany. Emerging Infectious Diseases, 2007, 13, 780-782.	4.3	96
81	Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. Aids, 2010, 24, S57-S65.	2.2	90
82	Tuberculosis trends in Eastern Europe and the former USSR. Tubercle and Lung Disease, 1994, 75, 400-416.	2.1	88
83	The global tuberculosis situation: Progress and problems in the 20th century, prospects for the 21st century. Infectious Disease Clinics of North America, 2002, 16, 1-58.	5.1	86
84	Global Burden and Epidemiology of Tuberculosis. Clinics in Chest Medicine, 2009, 30, 621-636.	2.1	85
85	Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-l.. Archives of Disease in Childhood, 1993, 68, 665-668.	1.9	78
86	Scale up: meeting targets in global tuberculosis control. Lancet, The, 2004, 363, 814-819.	13.7	75
87	Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infectious Diseases, The, 2013, 13, 690-697.	9.1	72
88	XDR-TB: entering the post-antibiotic era?. International Journal of Tuberculosis and Lung Disease, 2006, 10, 1185-7.	1.2	68
89	Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. Aids, 1995, 9, 267-274.	2.2	66
90	Evidence of SARS-CoV-2 RNA in an Oropharyngeal Swab Specimen, Milan, Italy, Early December 2019. Emerging Infectious Diseases, 2021, 27, 648-650.	4.3	64

#	Article	IF	Citations
91	Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bulletin of the World Health Organization, 2011, 89, 573-582.	3.3	61
92	Digital health for the End TB Strategy: developing priority products and making them work. European Respiratory Journal, 2016, 48, 29-45.	6.7	61
93	HighStaphylococcus aureus nasal carriage rate in patients with acquired immunodeficiency syndrome or AIDS-related complex. American Journal of Infection Control, 1990, 18, 64-69.	2.3	60
94	The Burden of Drug-Resistant Tuberculosis and Mechanisms for Its Control. Annals of the New York Academy of Sciences, 2001, 953b, 88-97.	3.8	59
95	Planning to improve global health: the next decade of tuberculosis control. Bulletin of the World Health Organization, 2007, 85, 341-347.	3.3	59
96	The World Health Organization standards for tuberculosis care and management. European Respiratory Journal, 2018, 51, 1800098.	6.7	57
97	Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. European Respiratory Journal, 2004, 24, 11-17.	6.7	53
98	Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops. European Respiratory Journal, 2011, 37, 950-959.	6.7	53
99	The new Stop TB Strategy and the Global Plan to Stop TB 2006-2015. Bulletin of the World Health Organization, 2007, 85, 327-327.	3.3	52
100	Global Tuberculosis Control: Toward the 2015 Targets and Beyond. Annals of Internal Medicine, 2015, 163, 52-58.	3.9	51
101	Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions. PLoS Medicine, 2016, 13, e1001965.	8.4	50
102	Latent Mycobacterium tuberculosis Infection. New England Journal of Medicine, 2015, 373, 1178-1180.	27.0	48
103	Resources Required for Global Tuberculosis Control. Science, 2002, 295, 2040-2041.	12.6	46
104	The health workforce crisis in TB control: a report from high-burden countries. Human Resources for Health, 2005, 3, 2.	3.1	46
105	Stopping tuberculosis in the 21st century: Goals and strategies. Respirology, 2010, 15, 32-43.	2.3	46
106	Tuberculosis elimination: dream or reality? The case of Cyprus. European Respiratory Journal, 2014, 44, 543-546.	6.7	46
107	Improving the TB case management: the International Standards for Tuberculosis care. European Respiratory Journal, 2006, 28, 687-690.	6.7	44
108	Epidemiology of Antituberculosis Drug Resistance in Saudi Arabia: Findings of the First National Survey. Antimicrobial Agents and Chemotherapy, 2013, 57, 2161-2166.	3.2	44

#	Article	IF	Citations
109	World TB Day 2014: finding the missing 3 million. Lancet, The, 2014, 383, 1016-1018.	13.7	44
110	WHO and the future of disease control programmes. Lancet, The, 2013, 381, 413-418.	13.7	43
111	Celebrating World Tuberculosis Day at the time of COVID-19. European Respiratory Journal, 2020, 55, 2000650.	6.7	41
112	Use of Digital Technology to Enhance Tuberculosis Control: Scoping Review. Journal of Medical Internet Research, 2020, 22, e15727.	4.3	41
113	Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). European Respiratory Journal, 2011, 38, 493-495.	6.7	40
114	Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002â€“11, and requirements to meet 2015 targets. The Lancet Global Health, 2013, 1, e105-e115.	6.3	39
115	WHO's End TB Strategy: From stopping to ending the global TB epidemic. Indian Journal of Tuberculosis, 2015, 62, 196-199.	0.7	37
116	Pneumocystis CariniiInfection of the Thyroid in a Hypothyroid Patient with AIDS: Diagnosis by Fine Needle Aspiration Biopsy*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 724-726.	3.6	36
117	Patients with Previously Treated Tuberculosis No Longer Neglected. Clinical Infectious Diseases, 2007, 44, 61-64.	5.8	36
118	Supervised Preventive Therapy for Latent Tuberculosis Infection in Illegal Immigrants in Italy. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1653-1655.	5.6	35
119	Tuberculosis: still a social disease [Editorial]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 6-8.	1.2	35
120	Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice. European Respiratory Journal, 2016, 48, 1571-1581.	6.7	35
121	Tuberculosis and HIV in people who inject drugs. Current Opinion in HIV and AIDS, 2012, 7, 345-353.	3.8	34
122	How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bulletin of the World Health Organization, 2002, 80, 939-45.	3.3	33
123	Facing Extensively Drug-Resistant Tuberculosis â€" A Hope and a Challenge. New England Journal of Medicine, 2008, 359, 636-638.	27.0	32
124	Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. European Respiratory Journal, 2014, 44, 1412-1417.	6.7	32
125	Build back stronger universal health coverage systems after the COVID-19 pandemic: the need for better governance and linkage with universal social protection. BMJ Global Health, 2020, 5, e004020.	4.7	32
126	The "vertical-horizontal" debates: time for the pendulum to rest (in peace)?. Bulletin of the World Health Organization, 2007, 85, 413-414.	3.3	32

#	Article	IF	Citations
127	Fatal Toxic Epidermal Necrolysis During Prophylaxis With Pyrimethamine and Sulfadoxine in a Human Immunodeficiency Virusâ€"Infected Person. Archives of Internal Medicine, 1988, 148, 2683.	3.8	30
128	Extrapulmonary Pneumocystis Infection. Annals of Internal Medicine, 1989, 111, 339.	3.9	29
129	Tuberculosis as a Major Global Health Problem in the 21st Century: A WHO Perspective. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 245-253.	2.1	29
130	Epidemiology of Tuberculosis in the World. Seminars in Respiratory and Critical Care Medicine, 1997, 18, 419-429.	2.1	28
131	Setting new targets in the fight against tuberculosis. Nature Medicine, 2013, 19, 263-263.	30.7	27
132	Splenectomy in patients with AIDS. American Journal of Hematology, 1989, 32, 184-189.	4.1	26
133	Costs and benefits of improving tuberculosis control: The case of Thailand. Social Science and Medicine, 1997, 44, 1805-1816.	3.8	26
134	The Global Plan to Stop TB, 2006-2015. International Journal of Tuberculosis and Lung Disease, 2006, 10, 238-9.	1.2	26
135	Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis. Lancet, The, 2004, 363, 320-324.	13.7	25
136	Tuberculosis and air travel: WHO guidance in the era of drug-resistant TB. Travel Medicine and Infectious Disease, 2008, 6, 177-181.	3.0	25
137	Modernizing Surveillance of Antituberculosis Drug Resistance: From Special Surveys to Routine Testing. Clinical Infectious Diseases, 2011, 52, 901-906.	5.8	25
138	Isoniazid preventive treatment: predictors of adverse events and treatment completion. International Journal of Tuberculosis and Lung Disease, 2013, 17, 903-908.	1.2	25
139	Target regimen profiles for treatment of tuberculosis: a WHO document. European Respiratory Journal, 2017, 49, 1602352.	6.7	25
140	Trends in tuberculosis in the UK. Thorax, 2018, 73, 702-703.	5.6	24
141	Clinical Features and Management of Severe Dermatological Reactions to Drugs. Drug Safety, 1990, 5, 39-64.	3.2	22
142	What Research Is Needed to Stop TB? Introducing the TB Research Movement. PLoS Medicine, 2011, 8, e1001135.	8.4	22
143	Multidrug-resistant tuberculosis in Eastern Europe: still on the increase?. European Respiratory Journal, 2012, 39, 1290-1291.	6.7	22
144	Tuberculosis control, and the where and why of artificial intelligence. ERJ Open Research, 2017, 3, 00056-2017.	2.6	22

#	Article	IF	Citations
145	A roadmap for zoonotic tuberculosis: a One Health approach to ending tuberculosis. Lancet Infectious Diseases, The, 2018, 18, 137-138.	9.1	22
146	Impact of socio-economic factors on Tuberculosis treatment outcomes in north-eastern Uganda: a mixed methods study. BMC Public Health, 2021, 21, 2167.	2.9	22
147	Validation of the surveillance system for new cases of tuberculosis in a province of Northern Italy. European Respiratory Journal, 1995, 8, 1252-1258.	6.7	21
148	Preventing and managing antimicrobial resistance: imperative for chest physicians. European Respiratory Journal, 2011, 37, 978-981.	6.7	21
149	A sustainable agenda for tuberculosis control and research. Lancet, The, 2012, 379, 1077-1078.	13.7	21
150	Children under 5â€…years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. European Respiratory Journal, 2017, 50, 1701414.	6.7	21
151	Managing tuberculosis in people who use and inject illicit drugs. Bulletin of the World Health Organization, 2013, 91, 154-156.	3.3	20
152	The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO/ERS consultation. European Respiratory Journal, 2015, 46, 307-311.	6.7	20
153	Ending infectious diseases in the era of the Sustainable Development Goals. Porto Biomedical Journal, 2017, 2, 140-142.	1.0	19
154	Tuberculosis control is crucial to achieve the MDGs. Lancet, The, 2010, 376, 940-941.	13.7	18
155	Active case-finding for TB in the community: time to act. Lancet, The, 2010, 376, 1205-1206.	13.7	17
156	Implementing the Global Plan to Stop TB, 2011â€“2015 â€“ Optimizing Allocations and the Global Fundâ€™s Contribution: A Scenario Projections Study. PLoS ONE, 2012, 7, e38816.	2.5	17
157	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. European Respiratory Journal, 2016, 47, 686-688.	6.7	17
158	Tuberculosis makes it onto the international political agenda for healthâ€¦finally. The Lancet Global Health, 2018, 6, e20-e21.	6.3	17
159	Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis. Emerging Infectious Diseases, 2012, 18, e2-e2.	4.3	17
160	Tuberculosis and poverty: what is being done [Counterpoint]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 431-432.	1.2	16
161	Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy. Journal of Clinical Medicine, 2020, 9, 101.	2.4	16
162	S. aureus nasal carriage among homosexual men with and without HIV infection. American Journal of Infection Control, 1991, 19, 98-100.	2.3	15

#	Article	IF	Citations
163	Issues Facing TB Control (7) Multiple Drug-Resistant Tuberculosis. Scottish Medical Journal, 2000, 45, 52-55.	1.3	15
164	Pleural Pneumocystis carinii Infection*. Chest, 1991, 99, 774-776.	0.8	14
165	Transforming the global tuberculosis response through effective engagement of civil society organizations: the role of the World Health Organization. Bulletin of the World Health Organization, 2011, 89, 616-618.	3.3	14
166	Cardiopulmonary Resuscitation in Patients With the Acquired Immunodeficiency Syndrome. Archives of Internal Medicine, 1988, 148, 2602.	3.8	13
167	Aiming for zero tuberculosis transmission in low-burden countries. Lancet Respiratory Medicine,the, 2017, 5, 846-848.	10.7	13
168	Tuberculosis research and development: seeding the future. Lancet Respiratory Medicine,the, 2018, 6, 242-244.	10.7	13
169	Epidemiology, Control and Treatment of Multidrug-Resistant Tuberculosis. Drugs, 1996, 52, 103-108.	10.9	12
170	Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study. European Respiratory Journal, 2001, 18, 369-375.	6.7	12
171	Limitations on Human Rights: Are They Justifiable to Reduce the Burden of TB in the Era of MDR- and XDR-TB?. Health and Human Rights, 2008, 10, 121.	1.3	12
172	TB deaths rank alongside HIV deaths as top infectious killer. International Journal of Tuberculosis and Lung Disease, 2016, 20, 143-144.	1.2	12
173	Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives. European Respiratory Journal, 2017, 50, 1701632.	6.7	12
174	Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance. European Respiratory Journal, 2012, 39, 802-804.	6.7	11
175	Group G streptococcal meningitis and sepsis in a patient with AIDS a method to biotype group G streptococcus. Diagnostic Microbiology and Infectious Disease, 1990, 13, 261-264.	1.8	10
176	Perspective: Weigh all TB risks. Nature, 2013, 502, S13-S13.	27.8	10
177	Ending tuberculosis in India: A political challenge & an opportunity. Indian Journal of Medical Research, 2018, 147, 217.	1.0	10
178	Waiting for the truth: is reluctance in accepting an early origin hypothesis for SARS-CoV-2 delaying our understanding of viral emergence?. BMJ Global Health, 2022, 7, e008386.	4.7	10
179	Linezolid for Extensively Drug-Resistant Tuberculosis. New England Journal of Medicine, 2013, 368, 290-291.	27.0	9
180	Toward Tuberculosis Elimination in Low-Incidence Countries: Reflections From a Global Consultation. Annals of Internal Medicine, 2014, 161, 670.	3.9	9

#	Article	IF	Citations
181	Numbers needed to treat to prevent tuberculosis. European Respiratory Journal, 2015, 46, 1838-1839.	6.7	9
182	Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action. European Respiratory Journal, 2017, 50, 1700946.	6.7	9
183	Molecular Evidence for SARS-CoV-2 in Samples Collected From Patients With Morbilliform Eruptions Since Late Summer 2019 in Lombardy, Northern Italy. SSRN Electronic Journal, 0, , .	0.4	8
184	Political rationale, aims, and outcomes of health-related high-level meetings and special sessions at the UN General Assembly: AÂpolicy research observational study. PLoS Medicine, 2022, 19, e1003873.	8.4	8
185	Prospective multicentre study on the evaluation of antituberculosis treatment results in Italy: comparison of the culture- versus the smear-based methods. European Respiratory Journal, 1999, 13, 900.	6.7	7
186	Drug-resistant tuberculosis: latest advances. Lancet Respiratory Medicine,the, 2013, 1, e9-e10.	10.7	7
187	Harnessing the Power of Data to Guide Local Action and End Tuberculosis. Journal of Infectious Diseases, 2017, 216, S669-S672.	4.0	7
188	Rebalancing the global battle against tuberculosis. The Lancet Global Health, 2014, 2, e71-e72.	6.3	6
189	Engaging health-care workers to reduce tuberculosis transmission. Lancet Infectious Diseases, The, 2016, 16, 883-885.	9.1	6
190	The Internet of Things to come: digital technologies and the End TB Strategy. BMJ Global Health, 2016, 1, e000038.	4.7	6
191	TB Elimination Requires Discovery and Development of Transformational Agents. Applied Sciences (Switzerland), 2020, 10, 2605.	2.5	6
192	Drug-resistant Tuberculosis in AIDS. Chest, 1990, 97, 511-512.	0.8	5
193	From Threat to Reality. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 216-217.	5.6	5
194	The European Respiratory Journal targets tuberculosis. European Respiratory Journal, 2010, 36, 714-715.	6.7	5
195	Precision global health: a roadmap for augmented action. Journal of Public Health and Emergency, 0, 4, 5-5.	4.4	5
196	Tuberculosis in the Western Pacific Region: Estimating the burden of disease and return on investment 2020â€“2030 in four countries. The Lancet Regional Health - Western Pacific, 2021, 11, 100147.	2.9	5
197	A Road Map to Control Malaria, Tuberculosis, and Human Immunodeficiency Virus/AIDS. Archives of Internal Medicine, 2009, 169, 1650.	3.8	4
198	Quality Tuberculosis Care. All Should Adopt the New International Standards for Tuberculosis Care. Annals of the American Thoracic Society, 2014, 11, 397-398.	3.2	4

#	Article	IF	Citations
199	Monitoring global health. BMJ: British Medical Journal, 2005, 330, 195.2.	2.3	4
200	Tuberculosis care and control. Bulletin of the World Health Organization, 2006, 84, 428-428.	3.3	4
201	Tuberculosis is a global health issue: challenges and need for new tools. BMC Proceedings, 2010, 4, .	1.6	3
202	Tuberculosis control: hard questions. Lancet, The, 2014, 384, 1744.	13.7	3
203	Migrant health and tuberculosis. International Journal of Tuberculosis and Lung Disease, 2017, 21, 599-600.	1.2	3
204	Evolution of the strategies for control and elimination of tuberculosis. , 0, , 36-61.		3
205	Hospital or home? Scripting a high point in the history of TB care and control. WHO South-East Asia Journal of Public Health, 2012, 1, 220.	0.7	3
206	Risk of Exposure to HIV-Infected Body Fluids Among Medical Housestaff. AIDS Patient Care and STDs, 1992, 6, 52-55.	0.1	2
207	Moving the goalposts for tuberculosis targets in Africa. Lancet, The, 2013, 382, 27.	13.7	2
208	Rapid impact of effective chemotherapy on transmission of drug-resistant tuberculosis: pity the guinea pig. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1009-1011.	1.2	2
209	Rebuttal: Evidence and uncertainties. International Journal of Tuberculosis and Lung Disease, 2002, 6, 651-3.	1.2	2
210	Tuberculosis and HIV infection. Lancet, The, 1993, 342, 1368-1369.	13.7	1
211	An African solution?. Lancet, The, 1999, 353, 1530.	13.7	1
212	Controlling multidrug-resistant tuberculosis in India â€“ Authors' reply. Lancet, The, 2007, 369, 742.	13.7	1
213	The history of the DOTS strategyAchievements and perspectives. , 2009, , 930-939.		1
214	Hurry up and wait? Accelerating access to the Three I's for HIV-TB [Editorial]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 853-854.	1.2	1
215	WHO's relationship with the Stop TB Partnership. Lancet, The, 2012, 379, 611-612.	13.7	1
216	Household tuberculosis interventionsâ€"how confident are we?. Lancet, The, 2013, 382, 1157-1159.	13.7	1

#	Article	IF	Citations
217	Tuberculosis, Public Health Aspects. , 2017, , 252-266.		1
218	No accountability, no resultsâ€"the difficult task of advocating for tuberculosis solutions. Lancet Infectious Diseases, The, 2019, 19, 353-354.	9.1	1
219	A postgraduate qualification in tuberculosisâ€"Message in a bottle. International Journal of Infectious Diseases, 2020, 92, S100-S102.	3.3	1
220	Synergy between government and non-governmental organizations in health: WHO and the Union collaboration in tuberculosis control. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 24, 100251.	1.3	1
221	DOTS and multidrug-resistant tuberculosis. Resurgent and Emerging Infectious Diseases, 2000, , 115-131.	0.2	1
222	Cardiopulmonary Resuscitation in Patients With Acquired Immunodeficiency Syndrome-Reply. Archives of Internal Medicine, 1989, 149, 2380.	3.8	0
223	A Pilot Study. AIDS Patient Care and STDs, 1991, 5, 120-124.	0.1	0
224	Extrapulmonary pneumocytosis in AIDS. Infectious Diseases Newsletter (New York, N Y), 1991, 10, 53-55.	0.4	0
225	Global Epidemiology of Tuberculosis. , 2004, , 33-43.		0
226	The principles of primary health care and social justice. Journal of Medicine and the Person, 2009, 7, 103-105.	0.1	0
227	The WHO Stop TB Strategy for the coming decade. , 2009, , 940-948.		0
228	Giving a voice to those who die young: the fatal impact of tuberculosis and HIV in South Africa. Future Microbiology, 2010, 5, 1641-1643.	2.0	0
229	Prevention and control of tuberculosis during air travel. Travel Medicine and Infectious Disease, 2010, 8, 79-80.	3.0	0
230	Here is diabetes in The Lancet's tuberculosis Series!. Lancet, The, 2010, 376, 1987-1988.	13.7	0
231	Tuberculosis, Epidemiology of. , 2013, , 353-380.		0
232	Tuberculosis Epidemiology. , 2017, , 229-240.		0
233	Harnessing the energy of the corporate sector to end TB: BE health. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 21, 100206.	1.3	0
234	A Multisectoral Approach to Tuberculosis Control and Elimination in the Era of the United Nations Sustainable Development Goals. , 2021, , 349-358.		0

#	Article	IF	Citations
235	Tuberculosis: WHO-Recommended Strategies and Global Health Perspectives. , 2021, , 37-45.		0
236	Basic and Descriptive Epidemiology of Tuberculosis. , 2021, , 29-36.		0
237	Global TB Control: Persisting Problem, Shifting Solutions. , 2009, , 243-255.		0